SkyePharma PLC has licensed rights to three topical drug delivery technologies, Crystalip, DermaStick and the ES-Gel system, from Bioglan Pharma PLC. Under the terms of the agreement SkyePharma has paid $9 million in cash and will obtain certain exclusive development and commercial rights in relation to new products from the Crystalip and DermaStick technologies and Read more about Skyepharma Licenses Dermatology Technology[…]